The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78

Leo Rasche¹, Johannes Duell¹, Charlotte Morgner², Manik Chatterjee³, Frank Hensel⁴, Andreas Rosenwald², Hermann Einsele¹, Max S. Topp¹*, Stephanie Brändlein²+*

1 Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany, 2 Institute of Pathology, University of Würzburg, Würzburg, Germany, 3 Comprehensive Cancer Center Mainfranken, Würzburg, Germany, 4 Patrys GmbH, Würzburg, Germany

Abstract

In contrast to other haematological malignancies, targeted immunotherapy has not entered standard treatment regimens for de novo or relapsed multiple myeloma (MM) yet. While a number of IgG-formatted monoclonal antibodies are currently being evaluated in clinical trials in MM, our study aimed to investigate whether the fully human IgM monoclonal antibody PAT-SM6 that targets a tumour-specific variant of the heat shock protein GRP78 might be an attractive candidate for future immunotherapeutic approaches. We here show that GRP78 is stably and consistently expressed on the surface on tumour cells from patients with de novo, but also relapsed MM and that binding of PAT-SM6 to MM cells can specifically exert cytotoxic effects on malignant plasma cells, whereas non-malignant cells are not targeted. We demonstrate that the induction of apoptosis and, to a lesser extent, complement dependent cytotoxicity is the main mode of action of PAT-SM6, whereas antibody dependent cellular cytotoxicity does not appear to contribute to the cytotoxic properties of this antibody. Given the favourable safety profile of PAT-SM6 in monkeys, but also in a recent phase I trial in patients with malignant melanoma, our results form the basis for a planned phase I study in patients with relapsed MM.

Introduction

Multiple myeloma (MM) is a malignant disorder characterized by clonal expansion of plasma cells in the bone marrow leading clinically to anaemia, bone destruction, monoclonal gammapathy, renal failure, hypercalcaemia and increased susceptibility to infections [1]. Although treatment options for MM patients have improved over the past decade, MM remains largely incurable. Particularly, relapsed and refractory MM is associated with survival times of less than 30 months [2] resulting in a clear need to develop novel therapeutic approaches across all lines of MM therapy.

Targeted immunotherapy using monoclonal antibodies (mAbs) has substantially improved the treatment of lymphoid malignancies resulting in better initial disease control and corresponding higher rate of remissions in many lymphoma patients [3]. In contrast, antibody-based immunotherapy has not been approved for standard treatment in MM [4] despite several clinical trials testing IgG formatted antibodies. At present, novel candidates including elotuzumab or daratumumab targeting the plasma cell associated antigens CD319 and CD38, respectively, [5,6] are being explored in phase I/II and III trials, but their success remains to be established [7].

In general, molecules that are selectively overexpressed on the cell surface of neoplastic cells and that play an important role in cell growth or survival represent attractive targets for immunotherapy. Binding of therapeutically effective mAbs exerts cytotoxic effects by directly inducing apoptosis or via complement-dependent cytotoxicity (CDC) or the activation of cytotoxic immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) [8].

The fully human IgM mAb PAT-SM6 was initially isolated from a patient with gastric cancer and was described to be part of the natural immunity. In a previous study, we could demonstrate that PAT-SM6 targets a tumour specific variant of the heat shock protein GRP78 (BIP, HSPA5) [9]. GRP78 is known to be an endoplasmic reticulum-related protein, but it is also expressed on the cell surface of various epithelial cancer cells [10] and increased expression levels of GRP78 in cancer cells have been correlated with an adverse prognosis and drug resistance [11]. In addition, we and others reported that PAT-SM6 also binds to oxidized low-density lipoprotein (LDL). The simultaneous binding of oxidized...
LDL and cell-surface GRP78 induces internalisation of oxidised LDL in malignant cells causing intracellular deposition of cholesterol and triglyceride esters which in turn triggers the cells to undergo apoptosis [12,13].

GRP78 expression data in human tumours, in vitro cell-based assays, and in vivo human tumour xenograft studies suggest that PAT-SM6 may be an effective anti-tumour agent in several indications. The safety of this antibody treatment was recently demonstrated in cynomolgus monkeys, but also in a phase I trial evaluating safety, pharmacokinetics, immunogenicity, pharmacodynamics and anti-tumour activity of PAT-SM6 in patients with recurrent in-transit cutaneous melanoma (ACTRN 1261000738077).

In this study, we investigate the target expression profile of the IgM antibody PAT-SM6 in primary MM cells and demonstrate anti-tumour effects and their potential underlying mechanisms.

Materials and Methods

Ethics Statement

This study was approved by the Ethics Committee of the Medical Faculty of the University of Wurzburg (reference no. 44/10) and IRB-approved written informed consent was obtained from all participants.

Cell Culture

Human multiple myeloma (MM) cell lines INA-6, NCI H929, MM1.S, OPM-2 and U266 were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany), ATCC (Manassas, VA), or kindly provided by M. Gramatzki (Kiel) [14] and maintained as previously described [15]. Primary CD138+ MM cells from patients were obtained using positive selection with CD138 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).

Antibodies

Anti-GRP78 antibody PAT-SM6 (fully human IgM) was produced as outlined elsewhere [16] and provided by Patrys Ltd. (Melbourne, Australia). Anti-GRP78 control mAb (rabbit IgG, ET-21) was obtained from Sigma-Aldrich (St. Louis, MO). The anti-CD20 antibody Rituximab (Roche) was used as complement activating control antibody in CDC studies. ChromPure IgM was used as isotype control (Dianova, Germany).

PAT-SM6 Immunostaining on Bone Marrow Paraffin Sections

Immunohistochemistry (IHC) with PAT-SM6 antibody or control antibodies on bone marrow paraffin sections and cytospin preparations was performed as previously described [17].

Flow Cytometry

Direct and indirect immunofluorescence flow cytometric analysis was performed using a FACScan with CellQuest Pro acquisition software (Beckman Coulter, Miami, FL). The expression of GRP78 on MM cells was assessed using anti-GRP78 IgG (rabbit), as well as PAT-SM6 followed by fluorescein isothiocyanate (FITC)-conjugated secondary antibodies (Abcam or Dako). Isotype controls (human IgM or rabbit IgG) were used for the assessment of unspecific binding. The expression of CD138 was assessed by incubating cells with C1q (Quidel A400) and PAT-SM6 or IgM isotype control (ChromPure) respectively. Cells were stained using murine anti C1q mAb (Quidel A401) and anti murine IgG conjugated to fluorescein (DAKO). Overlay was shown against unspecific C1q binding with IgM isotype control.

ELISA (Enzyme-linked Immunosorbent Assay)

96-well plates (Corning Costar® 3590, NY) were used for the ELISA experiments. Coating was performed overnight at 4°C with reagents diluted in 0.05 M sodium bicarbonate buffer, pH 9. Samples were prepared as triplicates. Following coating all steps were performed at room temperature. Between incubation steps plates were washed 3 times with PBS/0.05% Tween 20, pH 7.4. Blocking was performed with PBS/0.05% Tween 20/2%BSA, pH 7.4 for 2 h. Tetramethylbenzidine (TMB) substrate was added and the reaction was stopped with 3 M H2SO4. Absorbance was measured at 450 nm using an ELISA reader.

For complement factor q1 (C1q) binding analysis, plates were coated with antibody concentrations ranging from 0.5 μg/ml to 20 μg/ml using triplicates. After blocking plates were incubated with human C1q (Quidel A400) 2 μg/ml for 2 h followed by sheep anti human C1q-HRP (Abcam, ab 46191) for 2 h.

For IgM binding to recombinant GRP78, plates were coated with GRP78 (produced in HEK293 cells, kindly provided by Patrys GmbH) ranging from 0.1 to 10 μg/ml. After blocking plates were incubated with natural IgM antibodies 2 μg/ml for 5 h followed by incubation with anti-human IgM-HRP (Dako) diluted 3:5,000 for 2 h.

For competition studies, all wells were coated with 10 μg/ml GRP78. Increasing amounts of GRP78 or control protein with the same molecular weight were added to a solution of PAT-SM6 IgM (2 μg/ml in PBS/0.05% Tween 20/0.2%BSA, pH 7.4). After incubation for 3 h anti-human IgM-HRP (Dako) diluted 3:5,000 was added and incubated for 2 h.

Cytotoxicity Assays

MM cell lines (2×105 cells/ml) or CD138-purified patient MM cells were incubated with PAT-SM6 or human isotype control IgM (0–400 μg/ml) in 96-well plates for 48 h (primary MM cells) or 72 h (MM cell lines). MM cell lines were tested in RPMI containing 10% FCS. Primary MM cells were tested in RPMI containing 10% FCS and Il-6 (2.5 ng/ml).

Cell death was determined by FACS analysis using the guava via count kit (Millipore Merck, Darmstadt, Germany). Propidium iodide and L85-75 double positive cells were set as dead cells. Annexin and 7-AAD positive cells were determined using the Nexin kit (Milipore Merck) according to manufacturer’s protocol.

Caspase 3 Activation Assay using PAT-SM6 in the MM1.S Cell Line

Determination of caspase 3 activation was performed using the AC-DEVD-AMC protease assay (BD Biosciences Pharmingen) as previously described by Mashima et al. [18]. Briefly, 2×10^6 cells were incubated with PAT-SM6 or controls (isotype as negative control or staurosporin as positive control) in a 6-well plate in a total volume of 2 mL/well. After incubation for 3 h, 6 h, 24 or 48 h, respectively, cells were harvested, centrifuged at 13,000 rpm and stored at -20°C. Cell pellets were lysed (200 mM Tris pH 7.5, 2 M NaCl, 20 mM EDTA, 0.2% Triton X 100 lysis buffer), centrifuged, and supernatants were transferred to a 96-well plate. Reaction buffer (50 mM Pipes pH 7.4, 10 mM EDTA, 0.5% Chaps) was added to the wells with or without caspase 3 inhibitor (AG Scientific, San Diego, CA) and incubated overnight at room temperature. RFU counts were determined using a fluorescent reader.
CDC Assays

50 μl of cell suspension (10,000 cells per well) was added into each well of a 96-well plate followed by 50 μl of antibody dilution (starting from 1 μg/ml up to 400 μg/ml total concentration/well diluted in RPMI containing 1% FCS) of PAT-SM6, rituximab or controls. After incubation for 15 min, 50 μL complement (normal human complement, Quadel, San Diego, CA) was added. The plates were incubated for 2 hours at 37°C with 5% CO2. After incubation the plates were centrifuged at 2,000 rpm for 5 min and supernatant was discarded. 30 μl of PBS buffer and 270 μl of a prepared solution of propidium iodide and LDS75 (Via Count Reagent, Millipore) were added to each well. After incubation for 15 minutes in the dark, cell viability was examined by micro-capillary flow cytometry (Guava PCM96 platform) and the ratio of live to dead cells was calculated for each well by counting 2,000 events per well using Cytosoft software. All experiments were repeated at least three times.

CDC activity was assessed by alamar blue as described previously [19]. Briefly, 50 μl cell suspension (10,000 cells) was transferred into each well followed by 50 μl dilution of antibody PAT-SM6 or rituximab starting from 1 μg/ml up to 400 μg/ml total concentration/well and isotype control (Chrompure IgM 400 μg/ml total concentration/well). To set a control for 100% lysis a Triton-X100 solution (2.5% Vol%) was used. After incubation at 37°C and 5% CO2 for 15 min, 50 μl complement was added to each well, followed by 15 μl of alamar blue solution (10 μl/100 μl cell suspension according to manufacturer) after 2 h incubation. All dilutions were performed in RPMI containing 10% FCS. Plates were incubated for 16 hours at 37°C and 5% CO2 and subsequently analysed using a fluorescence reader. All experiments were repeated at least three times.

ADCC Assay

CFSE labelled MM cell line OPM-2 was incubated with PAT-SM6 (20 μg/ml or 50 μg/ml) or unrelated polyclonal IgM (Chrompure, Dianova, Germany). Peripheral blood mononuclear cells (PBMC) from healthy donors in an effector to target ratio of 25:1 or 50:1 in RPMI supplemented with 1% human serum were added. After incubation of 4 or 24 h cells were stained with 7-AAD for cell death determination and analysed by FACS. 7-AAD/CFSE double positive cells were set as MM cells killed by ADCC.

Antibody Induced NK Cell Activation Assessed by CD69 Expression

OPM-2 MM cells were incubated with PAT-SM6 or unrelated polyclonal IgM (Chrompure, Dianova, Germany) for 15 min on ice followed by centrifugation. Cells were transferred into a 24-well plate (flat bottom) and co-incubated with PBMC from a healthy donor in an effector to target ratio of 10:1 for 0 and 20 hours. NK cell activation was determined using CD56, CD3 and CD69 fluorescent conjugated antibodies (BD, Germany) analysed by FACS.

Statistical Analysis

In vitro experiments were repeated in triplicates, and the results are reported as mean with standard error. Statistical significance of differences observed in experimental versus control condition was determined using the Student t-test or Wilcoxon sum rank test. The minimal level of significance was P<0.05. The statistical analysis was performed using GraphPad prism 5.

Results

PAT-SM6 Specifically Binds to Primary MM Cells

A panel of 10 monoclonal patient-derived IgM antibodies was screened for their binding capacity to MM cells. All selected IgM antibodies had shown tumour reactivity with a broader panel of different carcinomas in previous studies [17]. The human IgM antibody PAT-SM6 showed strongest staining by immunohistochemistry (IHC) on cytospin preparations and displayed binding to all tested MM cell lines (INA-6, NCI H929, MM1.S, OPM-2 and U266) in FACS analysis (Fig 1A). Therefore, PAT-SM6 was selected for further analysis in primary human MM cells. Here, PAT-SM6 specifically reacted with CD138-purified cells from MM patients displaying 100% binding by FACS (Fig 1A). Furthermore, a homogenous membrane staining could be observed in cytospin preparations, whereas CD138+ normal plasma cells which were obtained from healthy volunteers showed no PAT-SM6 binding, indicating a tumour cell specific binding (Figure S1).

PAT-SM6 Binds to MM Cells in Bone Marrow Infiltrates in All Cases

To generate representative data on the expression pattern of the PAT-SM6 target structure in MM patients, immunohistochemical staining in bone marrow biopsies was performed. In total, 24 samples were evaluated, including 11 MM patients at primary diagnosis, 9 MM patients in first or later relapse (Table 1) and 4 samples from healthy donors. PAT-SM6 specifically bound to MM cells in all 20 samples with a homogenous staining pattern of 80–100% of tumour cells (mean: 92%), indicating that its target structure is stably expressed in MM throughout various stages of the disease. A statistically significant difference in the percentage of PAT-SM6 positively stained cells MM cells at primary diagnosis vs. relapse could be observed (87% vs. 97%, p = 0.01, Table 1). In 8 of 20 samples, staining was limited to MM cells and did not show any background reaction (Fig 1B). In 12 samples very minor background staining of less than 4% of nucleated cells was observed that affected mainly myeloid progenitors. The four healthy controls showed no PAT-SM6 binding reaction (representative example shown in Figure 1B).

GRP78 Target Confirmation by ELISA, Immunohistochemistry and FACS

We have previously shown that PAT-SM6 binds to a tumour-specific isoform of GRP78, a member of the HSP70 family, as well as to oxidized LDL [9,17]. Binding of PAT-SM6 to GRP78 and oxidized LDL induces a tumour cell specific apoptotic process, called lipoptosis [12]. Given the broad reactivity pattern of PAT-SM6 we first investigated whether GRP78 is also the target structure of this antibody on MM cells.

In ELISA binding studies, PAT-SM6 bound to recombinant GRP78 in a dose dependent manner, whereas other unrelated natural monoclonal IgM antibodies showed no reaction (Fig 2A). Findings were further validated in a competitive ELISA assay, in which unbound GRP78 reduced binding of PAT-SM6 on a GRP78 coated plate. A control protein with similar molecular weight showed no effect. Thus, GRP78 is the target structure of PAT-SM6 (Fig 2B).

We next analysed the expression pattern of GRP78 in MM cell lines and primary MM cells by FACS and immunohistochemistry (IHC) using a rabbit anti-GRP78 IgG antibody. GRP78 was expressed in all MM cell lines and primary MM cells tested. FACS analysis revealed the target to be expressed on the plasma membrane of the cells (Fig 2C). IHC staining of bone marrow
Figure 1. PAT-SM6 specifically binds to MM cell lines and primary human MM samples. A, INA-6, NCI H929, MM1.S, OPM-2 and U266 MM cell lines or CD138-purified patient MM cells were stained with PAT-SM6 (5 μg/mL, open histogram) or isotype control (gray histogram) followed by...
sections indicated that MM cells stained positive for wild-type GRP78, and that the staining pattern correlated with the pattern displayed by PAT-SM6 (Fig. 2D). However, in contrast to PAT-SM6, the rabbit anti-GRP78 IgG antibody reacted with non-malignant cells as well. These findings provide additional evidence that PAT-SM6 targets a tumour specific variant of GRP78 [9].

Taken together, the PAT-SM6 specific GRP78 variant is widely expressed on the cell surface of MM cells, but not on healthy cells.

**PAT-SM6 Mediates Cytotoxicity to MM Cells by Induction of Apoptosis and Complement Activation**

We previously demonstrated that PAT-SM6 induces apoptosis after cell surface binding to GRP78 followed by internalization into tumour cells [13]. To elucidate the ability of PAT-SM6 to induce apoptosis in MM cells as well, MM cell lines and primary MM cells were analysed by a propidium iodide/LDS75 based FACS assay after treatment with PAT-SM6. MM1.S, OPM-2, INA-6 and U266 cells displayed a dose dependent cell death when incubated with PAT-SM6. At the highest concentration, PAT-SM6 significantly increased the percentage of dead cells (median range: 33–74.3%, Fig. 3A). Interestingly, U266 cells showed the lowest antibody induced cytotoxic effect, in line with only modest binding of PAT-SM6 to these cells in FACS analysis (Fig. 1A).

We next sought to validate the apoptotic effect of PAT-SM6 in CD138-purified primary MM cells that were freshly obtained from MM patients (n = 11) and cultivated in the presence of IL-6. PAT-SM6 showed an induction of apoptosis in MM cells (mean: 58.2%; median range: 19.2–94.6%, Fig. 3B). Of note, samples from patients at initial diagnosis of MM (n = 8) and samples from relapsed patients (n = 3) showed no significant difference (p = 0.7) with mean apoptotic rates of 56.5% and 62.7%, respectively. We conclude that PAT-SM6 exerts apoptotic effects in MM cells from patients with *de novo* MM as well as in cells from patients with several relapses.

**Table 1. Immunohistochemical analysis of the PAT-SM6 target expression pattern in bone marrow biopsies of MM patients.**

| Primary Diagnosis | Pat. Nr. | MM Infiltration (CD138+) | PAT-SM6 stained CD138+ MM cells | SM-6 stained cells other than myeloma |
|-------------------|---------|--------------------------|---------------------------------|-------------------------------------|
|                   |         |                         |                                 |                                     |
|                   | 1       | 60%                      | 90%                             | myelopoiesis (5%)                   |
|                   | 2       | 25–30%                   | 100%                            | myelopoiesis (5%)                   |
|                   | 3       | 50–70%                   | 80–90%                          | myelopoiesis (5%)                   |
|                   | 4       | 40%                      | 90%                             | myelopoiesis (10%)                  |
|                   | 5       | 20–30%                   | 80–90%                          | myelopoiesis (5%)                   |
|                   | 6       | 30–40%                   | 80%                             | myelopoiesis (5%)                   |
|                   | 7       | 80–90%                   | 80%                             | none                                |
|                   | 8       | 70%                      | 100%                            | none                                |
|                   | 9       | 70–80%                   | 80–90%                          | none                                |
|                   | 10      | 60–70%                   | 90%                             | myelopoiesis (10%)                  |
|                   | 11      | 85%                      | 80%                             | none                                |
| **total**         |         | 87%                      |                                 | 4%                                  |
|                   |         | (range 80–100%)          |                                 | (range 0–10%)                       |

| Relapse           | Pat. Nr. | MM Infiltration (CD138+) | PAT-SM6 stained CD138+ MM cells | SM-6 stained cells other than myeloma |
|-------------------|---------|--------------------------|---------------------------------|-------------------------------------|
|                   |         |                         |                                 |                                     |
|                   | 1       | 70%                      | 80%                             | myelopoiesis (5%)                   |
|                   | 2       | 30%                      | 100%                            | none                                |
|                   | 3       | 20%                      | 90%                             | none                                |
|                   | 4       | 70–80%                   | 100%                            | none                                |
|                   | 5       | 40–50%                   | 100%                            | none                                |
|                   | 6       | 25–30%                   | 100%                            | myelopoiesis (10%)                  |
|                   | 7       | 70%                      | 100%                            | myelopoiesis (5%)                   |
|                   | 8       | 50%                      | 100%                            | myelopoiesis (5%)                   |
|                   | 9       | 20–30%                   | 100%                            | myelopoiesis (5%)                   |
| **total**         |         | 97%                      |                                 | 3.3%                                |
|                   |         | (range 80–100%)          |                                 | (range 0–10%)                       |

doi:10.1371/journal.pone.0063414.t001
Figure 2. Target validation, PAT-SM6 reacts with cell surface expressed GRP78. A, Sandwich ELISA with recombinant GRP78 and PAT-SM6. Plates were coated with GRP78, blocked and incubated with PAT-SM6 or other natural IgM antibodies as controls followed by incubation with anti-human IgM-HRP. PAT-SM6 showed binding to recombinant GRP78. B, Competitive ELISA: Plates were coated with GRP78 and increasing amounts of GRP78 or control protein were added to a solution of PAT-SM6 followed by anti-human IgM-HRP. Unbound GRP78 reduced binding of PAT-SM6 on a GRP78 coated plate. C, Surface expression GRP78 (black histogram) in MM cell lines is shown using an anti GRP78 IgG (rabbit) antibody. D, GRP78 expression in bone marrow biopsies was assessed by immunohistochemistry with anti GRP78 IgG, PAT-SM6 or positive control CD138. Primary MM cells were positive for GRP78 and the staining pattern correlates with the pattern displayed by PAT-SM6. In contrast to PAT-SM6, anti-GRP78 IgG also reacted with non-malignant cells. Images were captured using a Leica DM BL microscope, the Leica ICC HD digital camera and the Leica LAS EZ V2.1.0 software.

doi:10.1371/journal.pone.0063414.g002
In contrast, PBMCs isolated from blood of healthy donors showed no cytotoxicity when treated with PAT-SM6 (Fig. 3B) confirming the tumour specific cell death induced by PAT-SM6.

Cytotoxicity induced by PAT-SM6 was also observed in MM cell lines by AnnexinV/7-AAD staining and an increased number of AnnexinV/7-AAD double stained cells in primary MM cells (Fig. 3C). Finally, induction of apoptosis was proven by a caspase 3 activation assay in MM1.S cells, indicating antibody mediated apoptosis as the putative mode of action (Fig. 3D).

Since we had observed a minor background staining of PAT-SM6 in myeloid progenitor cells in some bone marrow sections by immunohistochemistry (Table 1), we wished to evaluate the specificity in more detail. We thus isolated CD33-positive myeloid progenitor cells from the bone marrow of a MM patient and performed binding and cytotoxicity studies as described above.

Figure 3. PAT-SM6 mediates cytotoxicity to patient MM cells and MM cell lines by induction of apoptosis. A, MM cell lines were incubated with various concentrations of PAT-SM6 or control (unrelated IgM at highest concentration) for 72 h. Cell death was determined by FACS (Propidium iodide/LDS75 double positive cells). B, CD138-purified primary MM cells at primary diagnosis (n = 8, dots) or relapse (n = 3, rectangle) were incubated for 48 h with PAT-SM6 or isotype in media containing IL-6 and 10% FCS. Dead cells were determined by FACS analysis (Propidium iodide/LDS75 double positive cells). As control, PBMCs from healthy volunteers were treated under the same conditions. In contrast to controls PAT-SM6 significantly induced programmed cell death. C, MM1.S cells were incubated with PAT-SM6 or controls (staurophorin as positive control) for 72 h. AnnexinV and 7AAD positive cells were assessed by flow cytometry. Percentage of 7-AAD/Annexin V double positive cells, Isotype: 14%, PAT-SM6:79% and positive control: 76%. D, MM1.S cells were incubated with PAT-SM6 or controls (staurophorin or isotype) for 6 h and caspase 3 activation was measured using the AC-DEVD-AMC protease assay. E, Bone marrow cells from a MM patient were CD33-purified to obtain myeloid progenitors and stimulated with PAT-SM6 or controls. No specific binding and subsequently no specific cytotoxicity was observed. F, Cells from the same patient as in E were CD138-isolated and incubated with PAT-SM6 (200 μg/mL) for 24 h. Specific PAT-SM6 binding and killing was observed.
PAT-SM6 neither showed reactivity with CD33-positive cells nor induction of any specific cytotoxic effect (Fig. 3E) suggesting an artificial background staining in immunohistochemical analyses. In contrast, CD138-positive MM cells from the same patient showed PAT-SM6 binding in FACS analysis and significant induction of cytotoxicity (Fig. 3F), again demonstrating the specific induction of cytotoxic effects by PAT-SM6.

**Complement dependent cytotoxicity (CDC).** Although IgM antibodies are described to be excellent complement binders, there is still conflicting data whether IgM antibodies can exert cytotoxic effects by complement dependent cytotoxicity. We therefore determined the capability of PAT-SM6 to bind and activate complement. PAT-SM6 showed clear, but moderate binding to C1q in an ELISA format compared to an unspecific IgM isotype control. However, the IgG antibody Rituximab serving as a positive control, displayed a stronger C1q binding capacity (Fig. 4A), which correlates with superior C1q binding properties of IgG antibodies in general.

To assess complement binding in a living cell system, PAT-SM6-mediated deposition of C1q on the surface of OPM-2 cells was assessed by FACS using human C1q and corresponding antibodies. C1q deposition was clearly improved with the addition of PAT-SM6 compared to cells treated with the isotype control (Fig. 4B).

In order to determine complement-dependent cytotoxicity, OPM-2 cells were co-incubated with various concentrations of PAT-SM6 and human complement for 2 h, followed by the measurement of lysed cells. PAT-SM6 treated cells showed a dose-dependent cell death with a maximum of 40% lysed cells. Due to the lack of CD20 expression in OPM-2 cells, Rituximab in the same concentrations displayed no specific activity (Fig. 4C).

**Antibody-dependent cellular cytotoxicity (ADCC).** While there is good evidence that some therapeutic IgG antibodies mediate antitumoural cytotoxicity via ADCC [5,20] the role of
ADCC in the cytotoxic properties of IgM antibodies is rather unclear. We therefore analysed the ADCC activity of PAT-SM6 in CFSE labelled target cells (OPM-2; PBMCs or purified natural killer (NK) cells as effectors in a FACS-based assay. No specific cell-mediated lysis of those target cells was observed (Figure S2).

To investigate putative immunomodulatory effects of IgM antibodies, we investigated CD69 and CD25 expression on effector subsets (T-, B- and NK cells) as surrogate markers for an early activation phenotype or as a marker indicating inhibition of immune effector cells. Whereas T- and B-cells showed no significant expression changes, we confirmed findings by Pricop and colleagues showing that unrelated polyclonal human IgM can inhibit NK cell activation [21]. In contrast to human polyclonal IgM, the monoclonal PAT-SM6 antibody did not change the activation marker CD69 on NK cells indicating diverse biological features of human monoclonal IgMs (Figure S3).

**Discussion**

Although novel therapeutic agents, such as thalidomide, lenalidomide and the proteasome inhibitor bortezomib have advanced treatment options for MM patients resulting in prolonged survival times [22,23], MM nevertheless still remains largely incurable and patients tend to relapse even after highly intensified treatment approaches [23].

While antibody-based therapies are widely employed in hematological malignancies, they have not yet entered standard treatment in MM. This may be due, at least in part, to the lack of optimal targets. However, several novel mAbs have been developed during the last years, including monoclonal IgG antibodies or related immune conjugates that specifically target CD38, CS1, CD40, CD74, CD70, HM1.24, interleukin-6 and β2-microglobulin (β2M) [8]. A panel of these IgG formatted antibodies are currently evaluated in phase I to III studies [7]. Most of the initial observations in MM suggest that these mAbs given as mono-therapy have limited antitumor activity; however, a combination approach with other anti-myeloma agents may be a promising new treatment strategy in myeloma.

We here show that the IgM antibody PAT-SM6 targets the heat shock protein GRP78, which is stably and consistently expressed on the surface of primary multiple myeloma cells from patients with de novo MM, but also from patients with multiple relapses. Binding of PAT-SM6 to the surface of MM cells results in the induction of apoptosis and CDC, but not ADCC, demonstrating that a fully human IgM antibody can specifically target and eliminate malignant plasma cells.

Natural IgM antibodies are produced from germ line immunoglobulin genes with few, if any, mutations. As a consequence of the low mutation frequency, natural IgMs have low binding affinity and a restricted binding repertoire. However, the multi-valency of the pentameric structure creates high avidity and oligo-reactivity to conserved structures (e.g. carbohydrates, phospholipids, nucleic acids, and heat shock proteins), which makes them promising therapeutic candidates. A single IgM antibody is able to bind multiple copies of its specific target on a tumour cell, leading to effective cross-linking of the targets and efficient induction of cell death.

Several monoclonal IgM antibodies have been developed as therapeutic agents and are administered in clinical trials where evidence of efficacy was gathered [24–27]. Despite the growing interest and clinical promise, however, IgM antibodies have so far failed to gain widespread commercial interest as these antibodies are considered to be difficult to handle in terms of production and purification. Due to the large size and the extensively glycosylated nature of these proteins, the production of sufficient quantities of functionally active recombinant IgMs is indeed challenging. However, over the last years, the availability of human therapeutic IgM in GMP-grade is becoming more feasible due to the implementation of recombinant expression systems like Per.C6® [28] and successful increase in fermentation scale [16] making IgM generation economically competitive to IgG antibodies. The Per.C6® cell derived IgM antibody PAT-SM6 proved to be safe in toxicity, toxicokinetics, and immunogenicity studies in cynomolgus monkeys, showing no adverse reactions. Moreover, data generated in humans from a phase I study in patients with recurrent in-transit cutaneous melanoma, demonstrated a good safety profile without any reported serious adverse events. In post-treatment biopsies it could be demonstrated that the melanoma cells are indeed reached and targeted by this IgM antibody in vivo (data not shown).

The results of our study suggest that the induction of programmed cell death (PCD) is the major effector mechanism of cell death in MM cells targeted by PAT-SM6. This finding is in line with previous observations in epithelial cancer types. The induction of apoptotic processes is a common feature of natural IgM antibodies as part of the immunosurveillance mechanisms against malignant cells [17]. PAT-SM6 also activates CDC in MM cells by recruiting the complement factor C1q. Compared to the induction of programmed cell death, complement dependent cytotoxicity appears to be moderate, but may represent an additive effect to the main effector mechanism. A possible explanation for this moderate CDC activity of PAT-SM6 could be that pentameric natural human antibodies, which can pass epithelial barriers via the polymeric immunoglobulin receptor, try to avoid damage to healthy tissues, e.g. by complement activation in the intestine or the lungs [29]. PAT-SM6, however, does not induce ADCC, in line with previously reported results of other IgM antibodies [30]. Thus, a combination therapy of PAT-SM6 with other anti-myeloma agents that induce ADCC, e.g. lenalidomide or proteasome inhibitors, might exert synergistic effects in inducing myeloma cell death [7].

We have previously shown that PAT-SM6 cross-reacts with both cell surface expressed GRP78 and oxidized LDL thereby inducing apoptosis in target cells [9,12,13]. GRP78 belongs to the group of heat shock proteins (HSP) which have attracted attention in MM in recent years, as their dysregulation may contribute to the pathogenesis of MM [31–33]. HSPs are ubiquitous molecular chaperones involved in posttranslational folding, stabilization, maturation and activation of various proteins that are essential mediators of signal transduction and cell cycle progression. Environmental and other stress inducing stimuli lead to an increased intracellular synthesis of HSPs [34]. At high levels, the chaperones protect the cell against ER stress-induced apoptosis and maintain cell viability after exposure to stress-inducing conditions [35]. The result is a complex network of regulators and protective mechanisms, which help the cell to respond to stress stimuli [36] and to prevent cellular degradation processes, induced by apoptosis and autophagocytosis. HSPs are normally cytoplasmic proteins, but under diverse pathological conditions they are over-expressed and found on the surface of cells where they may serve as cell-surface signalling receptors [37]. As in malignant cells hypoxia and glucose deprivation is considered to be a permanent matter of stress, it is not surprising that tumour cells up-regulate HSPs to prevent cellular and molecular damage [11,38,39].

GRP78 (BIP, HSPA5) is a member of the HSP70 family and cell-surface-located GRP78 is found in a variety of malignant tumours including breast, lung, gastric, hepatocellular and prostate cancers. The expression correlates with tumour progression,
metastasis formation and drug resistance [38]. Of note, natural antibodies to GRP78 were found in the serum of prostate cancer patients, which further points to the antigenic property of surface GRP78 [40,41].

In summary, we show that the PAT-SM6 target GRP78 is widely expressed on the surface of primary MM cells, but not on normal plasma cells or other hematopoietic or non-hematopoietic cells. Binding of PAT-SM6 to the surface of MM cells, results in the effective induction of apoptosis and CDC, thus making this natural IgM antibody an attractive novel agent in the armamentarium of treatments for MM patients. As a fully human antibody, PAT-SM6 may reduce the risk of host-protective immune responses. The favourable toxicity profiles of PAT-SM6 combined with its high avidity binding to the target GRP78 and its interaction with host immune effectors form the basis for a phase I multi-dose escalating study in patients with relapsed multiple myeloma. This trial commenced at the end of 2012 and is currently ongoing.

Supporting Information

Figure S1 PAT-SM6 displays a membrane staining in cytospin preparations of patients MM cells. CD138-purified primary MM cells were centrifuged by cytospin, fixed and permeabilised with acetone and incubated with PAT-SM6 or unrelated polyclonal IgM (Chrompure, Dianova, Hamburg, Germany) for 15 min on ice followed by centrifugation and subsequently CD138 isolation using magnetic beads. CD138 isolated cells from a healthy donor showed no binding when incubated with PAT-SM6. Images were captured with a Leica DM BL microscope, the Leica IFC HD digital camera and the Leica LAS EZ V2.1.0 software.

References

1. Palmbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364: 1046–1060.
2. Chanu-Khan AA, Girah S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 2612–2624.
3. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373: 1033–1040.
4. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC (2011) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 154: 745–754.
5. Tai YT, Dilloe M, Song W, Leiba M, Li XF, et al. (2008) Anti-CS1 humanized monoclonal antibody HuLac63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112: 1329–1337.
6. de Weers M, Tai YT, van de Veer MS, Bakker JM, Vink T, et al. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186: 1840–1848.
7. van de Donk NW, Kamps S, Mutis T, Lokhorst HM (2012) Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 154: 199–213.
8. Yang J, Yi Q (2011) Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res 1: 22–33.
9. Rauschert N, Brandlein S, Holzinger E, Hensel F, Muller-Hermelink HK, et al. (2008) A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest 88: 375–386.
10. Zhang Y, Liu R, Ni M, Gill P, Lee AS (2010) Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/Bip. J Biol Chem 285: 15055–15075.
11. Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67: 3496–3499.
12. Pohle T, Brandlein S, Ruoff N, Muller-Hermelink HK, Vollmers HP (2004) Lipotocin: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64: 3900–3906.
13. Brandlein S, Rauschert N, Rasche L, Dreyklaft A, Hensel F, et al. (2007) The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol Cancer Ther 6: 326–333.
14. Broeke-Heidrich K, Kretschmar AK, Pfeifer G, Hensel C, Loffler D, et al. (2004) Interleukin-6-dependent gene expression profiles in multiple myeloma. J Immunol 176: 754–764.
15. Stuhmer T, Arts J, Chatterjee M, Borowski J, Wolff A, et al. (2010) Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 149: 529–536.
16. Valavek C, Cole J, Hensel F, Ye P, Conner MA, et al. (2011) Production and Purification of a PER.C6-Expressed IgM Antibody Therapeutic. BioProcess International 9: 28–37.
17. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, et al. (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995–8005.
18. Mashima T, Naito M, Kataoka S, Kawai H, Tsuruo T (1995) Aspartate-based inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res Commun 209: 907–915.
19. Gerrissen AF, Bosch M, de Weers M, de Winkel JG, Parren PW (2010) High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. J Immunol Methods 352: 184–196.
20. Mosser M, Brunke P, Moser S, Puntener U, Schmidt C, et al. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393–4402.
21. Prucz I, Rabinowich H, Moriel PA, Sulica A, Whiteside TL, et al. (1993) Characterization of the Fc mu receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects. J Immunol 151: 3018–3029.
22. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516–2520.
23. Anderson KC (2011) New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011: 184–190.
24. Irie RF, Ollila DW, O’Day S, Morton DL (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 53: 110–117.
25. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C (1995) Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother Emphasis Tumor Immunol 17: 151–160.
26. Macmillan ML, Couriel D, Weidorf DJ, Schwab G, Havrilla N, et al. (2007) A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 109: 2657–2662.
27. Derkx B, Wittes J, McCloskey R (1999) Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 28: 770–777.
28. Tchoudakova A, Hemel F, Murillo A, Eng E, Foley M, et al. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs 1: 163–171.
29. Randall TD, Parkhouse RM, Corley RB (1992) J chain synthesis and secretion of hexameric IgM is differentially regulated by lipopolysaccharide and interleukin 5. Proc Natl Acad Sci U S A 89: 962–966.
30. Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, et al. (2011) Human monoclonal antibodies to sialyl-Lewisa (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 17: 1024–1032.
31. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, et al. (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109: 720–728.
32. Davenport EL, Moore HE, Dunkel AS, Sharp SY, Workman P, et al. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110: 2641–2649.
33. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, et al. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107: 1092–1100.
34. Lee AS (2003) The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504–510.
35. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, et al. (2007) Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38: 1547–1552.
36. Hendriksen LM (2004) The ER function BiP is a master regulator of ER function. Mt Sinai J Med 71: 289–297.
37. Misra UK, Gonzalez-Gronow M, Gawdi G, Wang F, Pizzol SV (2008) A novel receptor function for the heat shock protein Grp78: silencing of Grp78 gene expression attenuates alpha2M*-induced signalling. Cell Signal 16: 929–938.
38. Li J, Lee AS (2006) Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45–54.
39. Feldman DE, Chauhan V, Koong AC (2005) The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 3: 597–605.
40. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, et al. (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275–284.
41. Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urena C, Gawdi G, et al. (2006) Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66: 11424–11431.